Neuroimaging and endothelial function in vascular-related mild cognitive impairment
DescriptionIdentification of risk factors and biomarkers of neurodegenerative disease is essential in caring for the growing numbers of elderly. Imaging biomarkers provide non-invasive ways to look at brain function. A new PET imaging agent, Pittsburgh Compound B (PiB), that identifies brain amyloid is an exciting development in brain imaging that needs to be studied. We plan to study this imaging technique in normal volunteers and patients with a variety of neurodegenerative diseases to determine its utility. Long term followup of these subjects will allow us to understand the predictive ability of this new test.
Inclusion and Exclusion Criteria
- Age 30-100
- Subjects who have completed or are scheduled to undergo the neurological evaluation procedures in the Mayo Clinic Study of Aging, Mayo ADRC, or Mayo neurodegenerative disease clinics.
- Subjects unable to lie down without moving for 10 minutes
- Women who are pregnant or cannot stop breast feeding for 24 hours
- Claustrophobic patients unable to tolerate the scans
- Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc.
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.